Results 241 to 250 of about 7,203,866 (304)

Glucocorticoids: an enemy or a friend for the dermatologist? recommendations for proper use and safe discontinuation. [PDF]

Endocrine
Sali E, Paschou IA, Dimopoulou SM, Tagka A, Chasapi V, Nicolaidou E, Stratigos AJ, Peppa M, Paschou SA.   +8 more
europepmc   +1 more source

The Price Paradox of Biosimilar-Like Long-Acting Insulin

The American Journal of Managed Care, 2022
To describe the uptake and out-of-pocket (OOP) costs of Basaglar, the first long-acting insulin biosimilar, in a commercially insured population in the United States.Retrospective analysis of commercial pharmacy claims and pharmacy co-payment offsets.We assessed Basaglar uptake by examining trends in the composition of the long-acting insulin market in
Morgane C, Mouslim, Emaan S, Rashidi, Joseph F, Levy, Mariana P, Socal, Antonio J, Trujillo   +4 more
openaire   +3 more sources

Management of Diabetic Cats with Long-acting Insulin

Veterinary Clinics of North America: Small Animal Practice, 2013
This article provides an overview of the most important information regarding the long-acting insulins glargine, detemir, and protamine zinc insulin in diabetic cats. Dosing protocols are described in detail, which achieve high remission rates and optimal glycemic control.
Roomp, Kirsten, Rand, Jacquie S.
openaire   +6 more sources

Some of the next articles are maybe not open access.

Related searches:

Insulin detemir: A long-acting insulin product

American Journal of Health-System Pharmacy, 2006
The pharmacology, pharmacokinetics, efficacy and tolerability, safety, drug interactions, dosage and administration, cost, and place in therapy of insulin detemir are reviewed.Insulin detemir is a long-acting, neutral, and soluble insulin analogue with a lower within-subject variability of fasting plasma glucose levels than isophane insulin human (NPH ...
Melissa C, Jones, Mallika, Patel
openaire   +2 more sources

Long-acting insulin analogs and cancer

Nutrition, Metabolism and Cardiovascular Diseases, 2018
Hyperinsulinemia is a recognized risk factor for cancer and plays a major role for the increased cancer incidence in diabetic patients. Whether insulin analogs, and particularly long-acting analogs, worsen the pro-cancer effect of excess insulin is still controversial.In this paper we summarize the biological bases for the potential detrimental effect ...
Sciacca L, Vella V, Frittitta L, Tumminia A, Manzella L, Squatrito S, Belfiore A, Vigneri R.   +7 more
openaire   +3 more sources

Insulin glargine: A new long-acting insulin product

American Journal of Health-System Pharmacy, 2002
The pharmacodynamics, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of insulin glargine are reviewed. Current treatment regimens for patients with type 1 diabetes mellitus and some with type 2 are designed to provide a basal insulin level with intermittent preprandial insulin coverage. Insulin glargine precipitates
Lindsey, Reinhart, Chad A, Panning
openaire   +2 more sources

Insulin glargine: A systematic review of a long-acting insulin analogue

Clinical Therapeutics, 2003
Insulin glargine is the first long-acting basal insulin analogue indicated for subcutaneous administration once daily at bedtime in adults with type 1 or type 2 diabetes mellitus and pediatric patients aged > or = 6 years with type 1 diabetes. It differs in structure from native human insulin by 3 amino acids, a structural modification that provides a ...
Fei, Wang, Jana M, Carabino, Cunegundo M, Vergara   +2 more
openaire   +2 more sources

An Update on the Long‐Acting Insulin Analogue Glargine

Basic & Clinical Pharmacology & Toxicology, 2006
Abstract: For both type 1 and type 2 diabetes, tight glycaemic control is vital to reduce the risk of long‐term complications. However, this must be achieved with minimal risk of hypoglycaemia. Glargine is a new long‐acting insulin analogue with an action profile designed to overcome this and has now been in clinical use for a number of years.
Henriette, Thisted, Søren Paaske, Johnsen, Jørgen, Rungby   +2 more
openaire   +2 more sources

U300, a novel long-acting insulin formulation

Expert Opinion on Biological Therapy, 2014
Insulin glargine (100 U/ml; U100) was the first long-acting basal insulin analog to be introduced into clinical practice and it remains the most widely used. Although U100 is an effective and safe treatment, research is ongoing to optimize the time-action profile.
Gemma, Sutton, Joan, Minguet, Carmen, Ferrero, Peter, Bramlage   +3 more
openaire   +2 more sources